Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists

Abstract

The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist.

What is claimed is: 
     
         1 . A method of treating or ameliorating muscular dystrophy in a subject in need of treatment thereof, comprising administering a therapeutically effective amount of a thromboxane A 2  receptor antagonist to the patient. 
     
     
         2 . The method of  claim 1 , wherein the muscular dystrophy is fibrosis is selected from the group consisting of Duchenne MD (DMD), Becker MD, and Limb-Girdle MD. 
     
     
         3 . The method of  claim 1 , further comprising administering the thromboxane A 2  antagonist to the patient on a chronic basis. 
     
     
         4 . The method of  claim 3 , wherein the cardiac function of the patient is maintained or improved. 
     
     
         5 . The method of  claim 3 , wherein the thromboxane A 2  receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof. 
     
     
         6 . The method of  claim 3 , wherein the thromboxane A 2  receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium). 
     
     
         7 . The method of  claim 1 , wherein the thromboxane A 2  receptor antagonist is administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally. 
     
     
         8 . The method of  claim 1 , wherein the thromboxane A 2  receptor antagonist is administered parenterally. 
     
     
         9 . The method of  claim 1 , wherein the thromboxane A 2  receptor antagonist is administered orally. 
     
     
         10 . The method of  claim 3 , wherein the thromboxane A 2  receptor antagonist is administered prophylactically to prevent cardiomyopathy in the patient. 
     
     
         11 . The method of  claim 3 , wherein the thromboxane A 2  receptor antagonist is administered prophylactically to prevent gastrointestinal dysfunction in the patient. 
     
     
         12 . The method of  claim 3 , wherein the therapeutically effective amount is from about 50 mg to about 500 mg. 
     
     
         13 . The method of  claim 5 , wherein the therapeutically effective amount is from about 150 mg to about 350 mg per day and the ifetroban is administered orally. 
     
     
         14 . A method of treating cardiac and/or gastrointestinal dysfunction in a human patient suffering from muscular dystrophy, comprising chronically administering a therapeutically effective amount of a thromboxane A 2  receptor antagonist to the human patient. 
     
     
         15 . The method of  claim 14 , wherein the therapeutically effective amount is from about 100 mg to about 500 mg. 
     
     
         16 . The method of  claim 14 , wherein the thromboxane A 2  receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof. 
     
     
         17 . The method of  claim 16 , wherein the thromboxane A 2  receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium). 
     
     
         18 . The method of  claim 16 , wherein the therapeutically effective amount is from about, 150 mg to about 350 mg per day and the ifetroban is administered orally. 
     
     
         19 . The method of  claim 13 , wherein the gastrointestinal dysfunction is smooth muscle dysfunction. 
     
     
         20 . The method of  claim 16 , wherein the therapeutically effective amount of ifetroban provides improved ventricular function to the heart of the patient.